Skip to main content
. 2022 Jul 9;23(1):417–423. doi: 10.1080/15384047.2022.2088984

Figure 2.

Figure 2.

sIL-2 r Serum Concentration: sIL-2 r serum concentration (7,192 ng/ml) at first progression on 10/2018 leading to transition to second-line mogamulizumab; second progression (19,297 ng/ml) on 01/2019 leading to transition to third-line lenalidomide; sIL-2 r serum concentration (9,043 ng/ml) one month prior to initiation of 9-ING-41; and sIL-2 r serum concentration (2,094 ng/ml) at best response 15 months after initiation of 9-ING-41.